Super Session 8 - Cancer Immunotherapy – the universal cancer weapon?
Thursday, September 15, 2016
•
S9
•
11:15 AM
>
12:30 PM
•
Super Session 8 - Cancer Immunotherapy – the universal cancer weapon?
•
Plenary Room A3
Hosted by Oslo Cancer Cluster and co-hosted by AbbVie
Novel therapeutics stimulating the patient’s own immune system to combat cancer have revolutionized melanoma and lung cancer treatment. Cancer immunotherapy is ASCOs “advance of the year 2016”, and major R&D investments and intense partnering between academia, biotech and global pharma create novel insights and drive innovation. International experts from academia, biotech, and global pharma will present and discuss emerging concepts, current challenges, and how to overcome these. Key questions include how to select the best treatment or combination regimen for an individual patient and how novel concepts and combinations can benefit cancer types and patients so far not responding to cancer immunotherapy.
Moderator:
Prof. Inge Marie Svane, Director Center for Cancer Immune Therapy – CCIT Dept. of Oncology and Hematology, Herlev Hospital, University of Copenhagen
Speakers:
Dr. Khatereh Ahmadi, Executive Director, Oncology Search and Evaluation Lead, European Hub, MSD
Dr. Øyvind Arnesen, CEO, Ultimovacs
Prof. Karl Johan Malmberg, Oslo University Hospital and Karolinska Institutet
Dr. Vincent L. Giranda, Project Director, Oncology Development, AbbVie
|